



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Letter to the Editor

Editorial Response to Drs. Simone and Mancusi



Annette Langer-Gould, MD, PhD
Los Angeles Medical Center, Department of Neurology
1505 N Edgemont, 5th Floor, Los Angeles, CA 90027
Email: Annette.M.Langer-Gould@kp.org
Phone: (323) 804-4906
Fax: (626) 564-3409
To the editors:

We thank Drs. Simone and Mancusi for their thoughtful comments. We completely agree that perhaps the most important contribution of our study is the simple clinical and laboratory criteria we used to identify patients with COVID-19 who may benefit from anti-inflammatory treatments

As they eruditely point out, the stage of COVID-19 infection—ranging from early infection, to COVID-CS, to consolidated, irreversible tissue damage—appears to modify the effectiveness of anti-inflammatory, anti-viral and immune potentiating treatments. This effect modification by stage needs to be reported, and carefully considered when extrapolating results from randomized

controlled trials, case series and observational studies into clinical practice.

Annette Langer-Gould, MD PhD

Conflicts of Interests:

Annette Langer-Gould currently serves as a voting member on the California Technology Assessment Forum, a core program of the Institute for Clinical and Economic Review (ICER). She has received sponsored and reimbursed travel from ICER.

References: None.

Annette Langer-Gould MD, PhD*
Los Angeles Medical Center, Department of Neurology, Southern California Permanente Medical Group, 1505 N Edgemont, 5thFloor, Los Angeles, CA 90027, USA

* Corresponding Author:

Received 14 September 2020